Levi & Korsinsky notifies investors that it has commenced an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) concerning potential violations of the federal securities laws.
On April 3, 2025, The company disclosed that the FDA issued a second Complete Response Letter (CRL) for reproxalap, Aldeyra's lead dry eye disease drug candidate. The FDA's CRL cited a failure to demonstrate efficacy for reproxalap and flagged concerns with the design of Aldeyra’s most recent trial, including differences in baseline symptom scores that may have impacted the reliability of their trial results. Following this news, shares of Aldeyra Therapeutics, Inc. fell over 74% in intraday trading.
If you suffered a loss on your Aldeyra Therapeutics, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





